# D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis

## TL;DR

Extending anticoagulation therapy to 12 months with edoxaban reduces blood clots in cancer patients with isolated distal deep vein thrombosis, without increasing major bleeding risks.

## Contribution

This study shows that 12-month edoxaban treatment is more effective than 3-month treatment in reducing thrombotic events in cancer patients with isolated distal DVT, regardless of D-dimer levels.

## Key findings

- 12-month edoxaban treatment reduced thrombotic events in both low and high D-dimer subgroups.
- Major bleeding risk was not significantly increased with 12-month treatment in either D-dimer subgroup.
- The study found no interaction between D-dimer levels and treatment efficacy or safety.

## Abstract

•Compared with a 3-month treatment, a 12-month edoxaban treatment is superior in reducing thrombotic events regardless of the D-dimer levels.•A 12-month edoxaban treatment does not significantly increase the risk of major bleeding regardless of the D-dimer levels.

Compared with a 3-month treatment, a 12-month edoxaban treatment is superior in reducing thrombotic events regardless of the D-dimer levels.

A 12-month edoxaban treatment does not significantly increase the risk of major bleeding regardless of the D-dimer levels.

Cancer-associated isolated distal deep vein thrombosis (IDDVT) is a common complication in patients with cancer. The Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients with Cancer study revealed the superiority of 12- over 3-month edoxaban treatment with respect to thrombotic risk. However, it remains unclear whether D-dimer levels during anticoagulation influence the efficacy of extended anticoagulation. In this post hoc subgroup analysis, we stratified 519 patients into the low D-dimer (<1.0 μg/mL) (n = 308) and high D-dimer (≥1.0 μg/mL) (n = 211) subgroups based on D-dimer levels at 3 months. The cumulative incidence of a composite of symptomatic recurrent venous thromboembolism (VTE) or VTE-related death was lower in the 12-month edoxaban group than in the 3-month edoxaban group in both the low D-dimer (0.8% vs 5.6%; P = .02; odds ratio [OR], 0.12; 95% confidence interval [CI], 0.01-0.66) and high D-dimer (0.9% vs 10.2%; P = .01; OR, 0.11; 95% CI, 0.01-0.62) subgroups without interaction. Furthermore, there was no significant difference in the cumulative incidence of major bleeding between the 12- and 3-month groups in both the low D-dimer (3.6% vs 1.8%; P = .64; OR, 1.96; 95% CI, 0.47-9.67) and high D-dimer (18.3% vs 14.6%; P = .29; OR, 1.27; 95% CI, 0.60-2.75) subgroups without interaction. In conclusion, a 12-month edoxaban treatment for cancer-associated IDDVT was superior to a 3-month treatment in reducing thrombotic events, irrespective of D-dimer levels after 3 months of anticoagulation therapy. There was no significant increased risk of major bleeding in the 12-month edoxaban group relative to the 3-month edoxaban group regardless of the D-dimer levels at 3 months. This trial was registered at www.clinicaltrials.gov as #NCT03895502.